medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 4

<< Back Next >>

Ann Hepatol 2013; 12 (4)

Occult hepatitis B in patients on hemodialysis: a review

Fontenele AMM, Salgado FN, Ferreira ASP

Language: English
References: 60
Page: 359-363
PDF size: 81.45 Kb.


ABSTRACT

The hepatitis B virus (HBV) is one of the most frequently transmitted agents in dialysis units. Occult hepatitis B is characterized by HBV infection without detectable surface antigen (HBsAg) in the patient’s serum, a positive or negative HBV DNA marker result in the serum and a positive result in the liver tissue, which leads to the potential risk of transmission during renal replacement therapy service. There is variation in occult hepatitis B prevalence rates in this population across various studies that may be related to numerous factors. The presence of occult hepatitis B in individuals undergoing renal replacement therapy is important with regard to both the possibility of transmission and the consequences for the patient, especially the development of chronic liver disease and reactivation of the disease after renal transplantation.


REFERENCES

  1. Lai M, Yun-Fan L. Chronic Hepatitis B: past, present and future. Clin Liver Dis 2010; 14: 531-46.

  2. Brechot C, Degos F, Lugassy C, Thiers V, Zafrani S, Franco D, Bismuth H, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985; 312: 270-76.

  3. Chemin L, Zoulin F, Merle P, Arkhis A, Chevallier M, Kay A, Cova L, et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknow aetiology. J Hepatol 2011; 34: 447-54.

  4. Fang Y, Shang QL, Liu JY, Li D, Xu WZ, Teng X, Zhao HW, et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect 2009; 58: 383-8.

  5. Kara Y, Yilmaz Me, Suner A, Kadiroglu Ak, Isikoglu B. The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients. Vaccine 2004; 22: 3963-67.

  6. Zanetti Ar, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: A historical overview. Vaccine 2008; 26: 6266-73.

  7. Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology 2010; 15: 137-45.

  8. Raimondo G, Allain J-P, Brunetto M, Buendia MA, Chen D-S, Colombo M, Craxi A, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.

  9. Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat 2010; 17: 1-15.

  10. Penna A, Artini M, Cavallii A, Leverero M, Bertoletti A, Pilli M, Chisari FV, et al. Long-lasting memory T-cell responses following self limited acute hepatitis B. J Clin Invest 1996; 98: 1185-94.

  11. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymph. Nat Med 1996; 10: 1104-8.

  12. Guidotti LG, Rochoford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-9.

  13. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91.

  14. Lok SFA. Occult hepatitis B virus infection: Diagnosis, implications and management? J Gastroenterol Hepatol 2004; 19: S114-S117.

  15. Marcellin P, Giostra E, Martinot-Peignoux M, Loriot MA, Jeagle ML, Wolf P, Degott C, et al. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 1991; 100: 1432-4.

  16. Toberson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-86.

  17. Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HVB infection. Semin Immunopathol 2013; 35: 39-52.

  18. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008; 48: 1001-26.

  19. Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. Management of occult hepatitis B virus infection: an update for clinician. World J Gastroenterol 2011; 17: 1563-8.

  20. Bes M, Vargas V, Piron M, Casamitgana N, Esteban JI, Vilanova N, Pinacho A, et al. T cell responses and viral variability in blood donation candidates with occult HBV infection. J Hepatol 2012; 56: 765-74.

  21. Raimondo G, Pollicino T, Cacciolla I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-70.

  22. Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, Trabaud MA, et al. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol 2007; 79: 1075-81.

  23. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90: 13-23.

  24. Kalia H, Fabrizi F, Martin P. Hepatitis B virus and renal transplantation. Transpl Rev 2011; 25: 102-9.

  25. Ocana S, Casas ML, Buhigas I, Lledo JL. Diagnostic strategy for occult hepatitis B virus infection. World J Gastroenterol 2011; 17: 1553-7.

  26. Copolla N, Tonzielo G, Pisauturo M, Messina V, Guastafierro S, Fiori M, Iodice V, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 2011; 83: 1909-16.

  27. Arababadi MK, Ahmadabadi Bn, Daredor Hy, Kennedy D. Epidemiology of occult hepatitis B infection among thalassemic, hemophilia and hemodialysis patients. Hepat Mon 2012; 12: 315-9.

  28. Carreño V, Bartolomé J, Castillo I, Quiroga A. Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 2008; 18: 139-57.

  29. Allain J-P, Mihaljevic I, Gonzalez-Fraile MI, Grubbe K, Holm- Harritshoj L, Garcia JM, Brojer E, et al. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 2013. Doi: 10.1111/trf.12096.

  30. Silva CM, Costi C, Costa C, Michelon C, Oravec R, Ramos AB, Niel C, et al. Low rate of occult hepatitis B virus infection among anti-HBc positive blood donors living in a low prevalence region in Brazil. J Infect 2005; 51: 24-9.

  31. Rizwan AH. The burden of chronic kidney disease. BMJ 2006; 332: 763-74

  32. Wong PN, Fung TT, Mak SK, Lo KY, Tong GM, Wong Y, Loo CK, et al. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol 2005; 20: 1641-51.

  33. Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semi Dial 2008; 21: 440-6.

  34. Sesso RC, Lopes AA, Thomé FS, Lugon JR, Santos DR. Relatório do Censo Brasileiro de diálise de 2010 [2010 Report of the Brazilian Dialysis Census]. J Bras Nefrol 2011; 33: 442-7.

  35. Cendorologo-Neto M, Draibe SA, Silva AEB, Ferraz ML, Granato C, Pereira CAP, Sesso RC, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among hemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995; 10: 240-6.

  36. Fabrizi F, Marzano A, Messa P, Martin P, Lampertico P . Hepatitis B virus infection in the dialysis population: current perspectives. Int J Artif Organs 2008; 31: 386-94.

  37. Hanett JD, Parfrey PS, Kennedy M, Zeldis JB, Steinman TI, Guttman RD. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis 1988; 11: 210-3.

  38. Chen GD, Gu JL, Qiu J, Chen LZ. Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers. Tranpl Infect Dis 2013. Doi: 10.1111/tid.12065.

  39. Cabrerizzo M, Bartolomé J, De Sequeira P, Caramelo C, Carreño V. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. J Am Soc Neprhol 1997; 8: 1443-7.

  40. Hollinger FB, Habibollahi P, Daneshmand A, Alavian SM. Occult hepatitis B infection in chronic hemodialysis patients: Current concepts and strategy. Hepat Mon 2010; 10: 199-204.

  41. Minuk GY, Sun DF, Greenberg R, Zhanq M, Hawkins K, Uhanova J, Gutkin A, et al. Occult hepatitis B virus infection in a north American adult hemodialysis patient population. Hepatology 2004; 40: 1072-7.

  42. Fabrizzi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, Villa M, et al. Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 2005; 21: 1341-7.

  43. Teruel JL, Mateos LA, Fernández L, Ortuño J. Occult hepatitis B virus infection in patients treated with chronic hemodialysis. Nefrología 2005; 23: 83-4.

  44. Siagris D, Christofidou M, Triga K, Pagoni N, Theochris GJ, Goumenos D, Lekkou A, et al. Occult hepatitis B virus infection in hemodialysis patients with chronic HCV infection. J Nephrol 2006; 19: 327-33.

  45. Goral V, Okzul H, Tekes S, Sit D, Kadiroglu AK. Prevalence of occult HBV infection in haemodialysis patients with chronic HCV. World J Gastroenterol 2006; 7 3420-4.

  46. Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, Keles H. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 2006; 28: 729-35.

  47. Altindis M, Uslan I, Cetinkaya Z, Yusel S, Cifiçi IH, Demirturk N, Ozdemir M, et al. Investigation of hemodialysis patients in terms of the presence of occult hepatitis B. Mikrobiyol Bul 2007; 41: 227-33.

  48. Jardim RN, Gonçales NS, Pereira JS, Fais VC, Gonçales Junior FL. Occult hepatitis B virus infection in immunocompromised patients. Braz J Infect Dis 2008; 12: 300-5.

  49. Ersoy O, Yilmaz R, Arici M, Turgan C, Bayraktar Y. Prevalence of occult hepatitis B infection in hemodialysis patients. Dialysis Transplant 2008; 37: 362-8.

  50. Gwak GY, Huh W, Lee DH, Min BH, Koh KC, Kim JJ, Oh HY. Occult hepatitis B virus infection in chronic hemodialysis patients in Korea. Hepatogastroenterology 2008; 55: 1721-4.

  51. Di Stefano M, Volpe A, Stallone G, Tartaglia L, Prato R, Martinelli D, Pastore G, et al Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J Nephrol 2009; 22: 381-6.

  52. Motta JS, Mello FC, Lago BV, Perez RM, Gomes SA, Figueiredo FF. Occult hepatitis B virus infection and lamivudineresistant mutations in isolates from renal patients undergoing hemodialysis. J Gastroenterol Hepatol 2010; 25: 101-6.

  53. Mina P, Georgiadou SP, Rizos C, Dalekos GN, Rigopoulou EL. Prevalence of occult hepatitis B virus infection in hemodialysis patients from Central Greece. World J Gastroenterol 2010; 16: 225-31.

  54. Aghakhani A, Banifazl M, Kalantar E, Eslamifar A, Amadi F, Razeqhi E, Atabak S, et al. Occult hepatitis B virus infection in hemodialysis patients with isolated hepatitis B core antibody: a multicenter study. Ther Apher Dial 2010; 14: 349-53.

  55. Ismail H, Soliman M, Ismail N. Occult hepatitis B virus infection in Egyptian hemodialysis patients with or without hepatitis C virus infection. Pathol Lab Med Int 2010; 2: 113-20.

  56. Sav T, Gursoy S, Torun E, Sav NM, Unal A, Oymak O, Utas C. Occult HBV infection in continuous ambulatory peritoneal dialysis and hemodialysis patients. Ren Fail 2010; 32: 74-7.

  57. Abu El Makarem MA, Abdel Hamid M, Abdel Aleem A, Ali A, Shatat M, Sayed D, Deaf A, et al. Prevalence of occult hepatitis B virus infection in hemodialysis patients from Egypt with or without hepatitis C virus infection. Hepat Mon 2012; 12: 253-8.

  58. Joukar F, Mansour-Ghnael F, Beshraati S, Khosh-Sorour M. Occult hepatitis B infection in a hemodialysis population in Guilan province, northern Iran. Hemodial Int 2012; 16: 294-7.

  59. Albuquerque ACC, Coêlho MRCD, Lemos MF, Moreira RC. Occult hepatitis B virus infection in hemodialysis patiens in Recife, Satate of Pernambuco, Brazil. Rev Soc Bras Med Trop 2012; 45: 558-62.

  60. Fabrizzi F, Martin P. Management of hepatitis B and C virus infection before and after renal transplantation. Curr Opin Organ Transplant 2006; 11: 583-8.




2020     |     www.medigraphic.com